Ellsworth Advisors’s iRadimed IRMD Stock Holding History

Ellsworth Advisors’s Portfolio IRMD Stock Details IRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-11,177	Closed	-$1.05M	–	209
2026 Q2	$1.05M	Buy	11,177 +26	+0.2%	+$2.37K	0.17%	112
2026 Q1	$1.07M	Sell	11,151 -661	-6%	-$66.1K	0.2%	95
2025 Q4	$1.21M	Sell	11,812 -186	-2%	-$16K	0.24%	94
2025 Q3	$878K	Sell	11,998 -132	-1%	-$8.8K	0.19%	104
2025 Q2	$725K	Buy	12,130 +146	+1%	+$8K	0.18%	109
2025 Q1	$629K	Buy	+11,984	New	+$673K	0.17%	126
2024 Q1	–	Sell	-8,777	Closed	-$417K	–	188
2023 Q4	$417K	Buy	8,777 +209	+2%	+$8.79K	0.13%	135
2023 Q3	$337K	Buy	8,568 +120	+1%	+$5.58K	0.12%	139
2023 Q2	$403K	Buy	+8,448	New	+$381K	0.14%	119

Other funds holding IRMD

Copeland Capital Management Conshohocken, Pennsylvania $4.34B AUM 17.52% 1-Year Est. Return

Davidson Capital Management Corpus Christi, Texas $604M AUM 18.09% 1-Year Est. Return

Isthmus Partners Madison, Wisconsin $1.04B AUM 19.97% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

Kings Path Partners Sugar Land, Texas $380M AUM 12.42% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Ellsworth Advisors's IRMD Position: Q3 2026 in Review

Ellsworth Advisors sold out of iRadimed (IRMD) in Q3 2026, closing a stake of 11,177 shares — an estimated $1.05M sold.

Ellsworth Advisors first reported a position in IRMD in Q2 2023 and held it in 9 quarters. The position peaked at $1.21M in Q4 2025. 30 funds tracked by Wall St. Rank hold IRMD as of Q3 2026.

Ellsworth Advisors reported no remaining iRadimed position as of Q3 2026 after selling out during the quarter.
Ellsworth Advisors sold 11,177 iRadimed shares in Q3 2026, an estimated $1.05M.
Ellsworth Advisors first reported a position in iRadimed in Q2 2023 and held it in 9 quarters.
Ellsworth Advisors's iRadimed position peaked at $1.21M in Q4 2025.
30 funds tracked by Wall St. Rank held iRadimed as of Q3 2026.

Based on Ellsworth Advisors's 13F filing for Q3 2026, filed 15 Oct 2026.